Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up2.740 +0.060 (+2.239%)
Others

07/06/2018 17:09

Sino Biopharm (01177) drug approved for drug registration

[ET Net News Agency, 7 June 2018] Sino Biopharmaceutical (01177) said the "Calcium
Levofolinate for Injection", a generic drug developed by its subsidiary Chia-Tai Tianqing
Pharmaceutical Holdings Co. Ltd has obtained the approval for drug registration granted by
the National Drug Administration of the People's Republic of China.
Calcium levofolinate for injection can be used in conjunction with 5-fluorouracil to
treat gastric cancer and colorectal cancer. Calcium levofolinate is mainly used for the
treatment of osteosarcoma after treatment with highdose methotrexate, with clear clinical
positioning and competitive strengths. (HL)

Back to Others

Remark: Real time quote last updated: 25/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.